Reduced High-Frequency Hearing for Speech Perception
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how blocking high-pitched sounds affects speech comprehension. It focuses on individuals who hear normally within a range of 250-8000 Hz. The study targets native American English speakers with normal hearing who might notice differences in understanding speech when high-frequency sounds are reduced. Those with normal hearing who often rely on high pitches may find this trial suitable. As an unphased trial, it offers a unique opportunity to contribute to understanding speech perception without the constraints of traditional clinical trial phases.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this method is safe for speech perception?
Research has shown that changes in hearing at high frequencies can begin even before age 10. One study found that young people have less sensitivity to these frequencies. Another study suggested that high-frequency hearing loss might occur before more noticeable hearing problems develop. While these findings indicate that high-frequency hearing loss can happen early, they don't directly relate to the safety of the treatment under study.
For this trial, detailed safety information is unavailable, and the trial phase is labeled as "Not Applicable." This usually means the study focuses on understanding a concept rather than testing a new drug or procedure. No specific safety evidence is mentioned for reducing extended high-frequency hearing. However, since this trial does not test a new medication or invasive treatment, it is likely considered safe for participants.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores a novel approach to improving speech perception by enhancing audibility in the extended high-frequency range. Unlike traditional hearing aids that primarily focus on amplifying lower frequency sounds, this treatment targets the higher frequencies that are critical for understanding speech in noisy environments. By potentially improving high-frequency hearing, this method could offer a significant advantage for people with normal hearing who still struggle with speech perception, especially in challenging listening situations. This trial aims to uncover new insights into the role of high-frequency sounds in everyday communication.
What evidence suggests that reduced extended high-frequency audibility might be an effective treatment for high-frequency hearing loss?
Research shows that very high-pitched sounds above 8 kHz are important for normal hearing and can enhance speech comprehension. Losing these sounds, such as when they are filtered out, can hinder speech understanding, especially in noisy environments. Some studies have found no major difference in speech comprehension between those who struggle to hear these high-pitched sounds and those who do not. However, other research indicates that losing these sounds can complicate speech understanding in challenging listening situations. This mixed evidence suggests that these high-pitched sounds are crucial for clear hearing, but results can vary. The trial will include normal-hearing listeners to further investigate the impact of reduced extended high-frequency audibility on speech perception.16789
Are You a Good Fit for This Trial?
This trial is for people who have normal hearing within the range of 250-8000 Hz and are native speakers of American English. It's not suitable for those with any level of hearing loss or non-native speakers of American English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo speech perception testing with low-pass filtered speech
Follow-up
Participants are monitored for any immediate effects post-testing
What Are the Treatments Tested in This Trial?
Interventions
- Reduced extended high-frequency audibility
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brian Monson
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator